Free Trial
Invest Smarter with A.I. Powered Investing Tools and ResearchGet 30 Days Free

Genmab A/S (OTCMKTS:GNMSF) Sees Large Increase in Short Interest

Written by MarketBeat
Updated September 18, 2025
Genmab A/S logo with Medical background

Key Points

  • Genmab A/S experienced a 148.7% increase in short interest in August, rising from 22,800 shares to 56,700 shares by August 31st.
  • The company's stock remains stable at $284.18 with a market capitalization of $18.78 billion and a price-to-earnings ratio of 14.27.
  • In its latest quarterly earnings, Genmab reported an EPS of $5.42, surpassing estimates and reflecting a revenue of $925 million, though falling short of analysts' expectations.
  • Five stocks we like better than Genmab A/S.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 56,700 shares, a growth of 148.7% from the August 15th total of 22,800 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is currently 283.5 days. Currently, 0.1% of the shares of the stock are short sold. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 200 shares, the short-interest ratio is currently 283.5 days.

Genmab A/S Stock Performance

Shares of OTCMKTS:GNMSF traded down $12.70 on Thursday, reaching $272.30. The company's stock had a trading volume of 24 shares, compared to its average volume of 240. The company has a 50-day simple moving average of $238.88 and a 200 day simple moving average of $215.91. The company has a market cap of $17.99 billion, a P/E ratio of 13.67 and a beta of 0.90. Genmab A/S has a 52-week low of $170.00 and a 52-week high of $285.00.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.99 by $1.43. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.